mRNA Translation Modulators Pipeline

The high scale automation and integrated technologies in our platform enabled us to develop a broad pipeline across 18 different discovery programs in various therapeutic areas. With our tremendous expertise in mRNA biology, we were able to advance them at unprecedented speed and success rate.

Anima wholly owned pipeline programs are in Fibrosis (tissue selective Collagen I translation inhibitors across several fibrotic diseases), Oncology (c-Myc and K-Ras translation inhibitors with multiple, tumor specific mechanisms of action), Infectious diseases (RSV viral proteins translation inhibitors) and Neuroscience (Tau - Alzheimer’s disease and pain - Nav1.7 translation inhibitors) with additional programs in Repeat Associated Diseases. In addition to our own pipeline, we established strategic collaborations with Pharma in partnered programs including our large scale collaborations with Lilly and Takeda Pharmaceuticals.

Indication Target
Discovery
Optimization
IND enabling
Anima owned
Fibrosis
Lung Fibrosis 1
Collagen-1 2
3
Liver Fibrosis 4
Oncology
c-Myc tumors c-Myc 5
6
7
mKRAS tumors mKRAS 8
Infectious diseases
Respiratory RSV 9
10
Neuroscience
Alzheimer TAU 11
Repeat diseases Undisclosed 12
Pain Nav 1.7 13
Partnered
Huntington mHTT 14
Undisclosed takeda logo lilly logo 15
Undisclosed 16
Undisclosed 17
Undisclosed 18
Anima owned
Partnered
Area Indication mRNA modulation Target
Discovery
Optimization
IND enabling
Fibrosis Lung Fibrosis 1
Collagen-1 2
3
Liver Fibrosis 4
Oncology c-Myc tumors c-Myc 5
6
7
mKRAS tumors mKRAS 8
Infectious diseases Respiratory RSV 9
10
Neuroscience Alzheimer TAU 11
Repeat diseases Undisclosed 12
Pain Nav 1.7 13
Undisclosed takeda logo lilly logo 14
Huntington mHTT 15
Undisclosed 16
Undisclosed 17
Undisclosed 18